ArticleVeterinary research2025
A novel chimpanzee adenovirus vector vaccine for protection against infectious bronchitis and Newcastle disease in chickens.
Article in Veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Development and immunological evaluation of a multi-antigen recombinant adenovirus vaccine candidate against PRRSV and PCV2.BMC veterinary research · 2026Article
- Molecular Characterization of Publicly Available NDV F Gene Sequences From Bangladesh (2010-2024).Veterinary medicine international · 2026Article
- Emergence of novel QX-type IBV in China: molecular insights into unique S protein cleavage sites, antigenic drift, and enhanced pathogenicity (2025).BMC veterinary research · 2025Article
- An adenovirus-vectored recombinant vaccine confers passive immunity protection from swine acute diarrhea syndrome coronavirus challenge in neonatal mice.Virologica Sinica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The development of effective poultry vaccines is crucial for maintaining flock health and productivity. In this study, we developed and evaluated a recombinant chimpanzee adenovirus vaccine (PAD-S1-HN) that simultaneously expresses the infectious bronchitis virus (IBV) spike subunit protein S1 and Newcastle disease virus (NDV) hemagglutinin-neuraminidase HN protein. The recombinant virus was successfully rescued in HEK293 cells, and transmission electron microscopy confirmed its typical adenoviral morphology. The expression of the IBV S1 and NDV HN proteins was validated by indirect immunofluorescence assay and western blotting. The vaccine demonstrated genetic stability over multiple passages and exhibited growth kinetics similar to those of the empty chimpanzee adenovirus vector. In animal trials, PAD-S1-HN effectively induced IBV- and NDV-specific antibodies, increased key cytokine levels, and stimulated mucosal immune responses, resulting in reduced viral loads, and alleviated clinical symptoms in vaccinated chickens. These findings indicate that the PAD-S1-HN vaccine provides strong immunogenicity and protective efficacy against IBV and NDV infections. Therefore, it presents a promising alternative to conventional vaccines, offering a novel approach for improving poultry disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.